2024 Q2 Form 10-Q Financial Statement
#000149315224020652 Filed on May 20, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q4 |
|---|---|---|---|
| Revenue | $2.000K | $13.00K | $0.00 |
| YoY Change | |||
| Cost Of Revenue | $3.000K | $3.000K | |
| YoY Change | |||
| Gross Profit | -$1.000K | $10.00K | |
| YoY Change | |||
| Gross Profit Margin | -50.0% | 76.92% | |
| Selling, General & Admin | $308.0K | $348.0K | $337.0K |
| YoY Change | -30.32% | -19.07% | -21.63% |
| % of Gross Profit | 3480.0% | ||
| Research & Development | $96.00K | $60.00K | $74.00K |
| YoY Change | 1271.43% | 566.67% | 23.33% |
| % of Gross Profit | 600.0% | ||
| Depreciation & Amortization | $6.000K | $6.000K | $7.000K |
| YoY Change | 0.0% | ||
| % of Gross Profit | 60.0% | ||
| Operating Expenses | $404.0K | $408.0K | $411.0K |
| YoY Change | -10.02% | 4433.33% | -16.12% |
| Operating Profit | -$405.0K | -$398.0K | |
| YoY Change | -9.8% | -8.72% | |
| Interest Expense | -$130.0K | -$22.00K | -$32.00K |
| YoY Change | -1400.0% | 10.0% | -420.0% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$130.0K | -$22.00K | $713.0K |
| YoY Change | -1183.33% | 15.79% | -892.22% |
| Pretax Income | $181.0K | -$1.244M | $270.0K |
| YoY Change | -152.92% | 328.97% | -147.37% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | $181.0K | -$1.244M | $270.0K |
| YoY Change | -152.92% | 330.45% | -147.37% |
| Net Earnings / Revenue | 9050.0% | -9569.23% | |
| Basic Earnings Per Share | $0.00 | $0.00 | |
| Diluted Earnings Per Share | $0.00 | $0.00 | $0.00 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 451.1M shares | 416.7M shares | 284.1M shares |
| Diluted Shares Outstanding | 453.5M shares | 380.3M shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $158.0K | $373.0K | $222.0K |
| YoY Change | 216.0% | 273.0% | 270.0% |
| Cash & Equivalents | $158.0K | $373.0K | $222.0K |
| Short-Term Investments | |||
| Other Short-Term Assets | $9.000K | ||
| YoY Change | |||
| Inventory | $13.00K | $14.00K | $14.00K |
| Prepaid Expenses | |||
| Receivables | $17.00K | $1.000K | |
| Other Receivables | $17.00K | $30.00K | $42.00K |
| Total Short-Term Assets | $197.0K | $418.0K | $278.0K |
| YoY Change | 118.89% | 254.24% | 251.9% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $2.000K | $2.000K | $3.000K |
| YoY Change | 100.0% | 100.0% | 50.0% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | |||
| YoY Change | |||
| Total Long-Term Assets | $262.0K | $240.0K | $196.0K |
| YoY Change | 129.82% | 101.68% | 55.56% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $197.0K | $418.0K | $278.0K |
| Total Long-Term Assets | $262.0K | $240.0K | $196.0K |
| Total Assets | $459.0K | $658.0K | $474.0K |
| YoY Change | 125.0% | 177.64% | 131.22% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $22.00K | $24.00K | $51.00K |
| YoY Change | -45.0% | -40.0% | -27.14% |
| Accrued Expenses | $291.0K | $679.0K | $109.0K |
| YoY Change | -42.94% | 61.67% | 75.81% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $78.00K | $890.0K | $875.0K |
| YoY Change | -66.52% | 43.55% | 26.26% |
| Long-Term Debt Due | $1.398M | $2.160M | $1.203M |
| YoY Change | -1.55% | 50.0% | -21.37% |
| Total Short-Term Liabilities | $2.615M | $3.825M | $3.027M |
| YoY Change | 2.55% | 44.45% | 9.36% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $2.615M | $3.825M | $3.027M |
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $2.615M | $3.825M | $3.027M |
| YoY Change | 2.71% | 44.45% | 9.36% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$7.389M | -$7.570M | -$6.326M |
| YoY Change | 43.75% | 57.77% | 40.3% |
| Common Stock | $45.00K | $41.00K | $31.00K |
| YoY Change | 104.55% | 86.36% | 47.62% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | -$2.142M | -$3.153M | -$2.539M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $459.0K | $658.0K | $474.0K |
| YoY Change | 125.0% | 177.64% | 131.22% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | $181.0K | -$1.244M | $270.0K |
| YoY Change | -152.92% | 330.45% | -147.37% |
| Depreciation, Depletion And Amortization | $6.000K | $6.000K | $7.000K |
| YoY Change | 0.0% | ||
| Cash From Operating Activities | -$185.0K | -$257.0K | -$187.0K |
| YoY Change | 105.56% | 164.95% | 107.78% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | |||
| YoY Change | |||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$28.00K | -$50.00K | -$57.00K |
| YoY Change | |||
| Cash From Investing Activities | -$28.00K | -$50.00K | -$57.00K |
| YoY Change | |||
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 0.000 | $456.0K | 307.0K |
| YoY Change | -100.0% | 223.4% | 514.0% |
| NET CHANGE | |||
| Cash From Operating Activities | -185.0K | -$257.0K | -187.0K |
| Cash From Investing Activities | -28.00K | -$50.00K | -57.00K |
| Cash From Financing Activities | 0.000 | $456.0K | 307.0K |
| Net Change In Cash | -213.0K | $152.0K | 63.00K |
| YoY Change | 326.0% | 280.0% | -257.5% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$185.0K | -$257.0K | -$187.0K |
| Capital Expenditures | |||
| Free Cash Flow | |||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
225248108 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
225248108 | shares |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
60000 | usd |
| CY2024Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2023Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
usd | |
| CY2024Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
usd | |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
usd | |
| CY2023Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
usd | |
| CY2023Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
usd | |
| CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
usd | |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
usd | |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
usd | |
| CY2023Q1 | APYP |
Financial Expenses Net
FinancialExpensesNet
|
usd | |
| CY2023Q1 | APYP |
Research And Development Expenses Capitalization
ResearchAndDevelopmentExpensesCapitalization
|
usd | |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
usd | |
| CY2023Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
usd | |
| CY2024Q1 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
usd | |
| CY2023Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
usd | |
| CY2024Q1 | us-gaap |
Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium
AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium
|
usd | |
| CY2024Q1 | APYP |
Conversion Of Convertible Loan
ConversionOfConvertibleLoan
|
usd | |
| CY2024Q1 | APYP |
Decrease Of Notes Purchased
DecreaseOfNotesPurchased
|
usd | |
| CY2024Q1 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
usd | |
| CY2024Q1 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
usd | |
| CY2022Q4 | APYP |
Convertible Amortized Cost
ConvertibleAmortizedCost
|
usd | |
| CY2024Q1 | APYP |
Transition From Convertible Loans Measured At Fair Value To Measurement At Amortized Cost
TransitionFromConvertibleLoansMeasuredAtFairValueToMeasurementAtAmortizedCost
|
usd | |
| CY2024Q1 | us-gaap |
Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
|
usd | |
| CY2024Q1 | APYP |
Financial Expenses Related To Transition From Fair Value Measurement To Amortized Cost
FinancialExpensesRelatedToTransitionFromFairValueMeasurementToAmortizedCost
|
usd | |
| CY2024Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1000 | usd |
| CY2024Q1 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
30000 | usd |
| CY2023Q4 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
42000 | usd |
| CY2024Q1 | us-gaap |
Inventory Net
InventoryNet
|
14000 | usd |
| CY2024Q1 | us-gaap |
Assets Current
AssetsCurrent
|
418000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
238000 | usd |
| CY2024Q1 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
240000 | usd |
| CY2024Q1 | us-gaap |
Assets
Assets
|
658000 | usd |
| CY2024Q1 | us-gaap |
Accounts Payable Trade Current
AccountsPayableTradeCurrent
|
24000 | usd |
| CY2024Q1 | us-gaap |
Accounts Payable Other Current
AccountsPayableOtherCurrent
|
679000 | usd |
| CY2024Q1 | APYP |
Convertible Amortized Cost Current
ConvertibleAmortizedCostCurrent
|
811000 | usd |
| CY2024Q1 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
2160000 | usd |
| CY2024Q1 | us-gaap |
Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
|
72000 | usd |
| CY2023Q4 | us-gaap |
Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
|
204000 | usd |
| CY2024Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3825000 | usd |
| CY2024Q1 | us-gaap |
Liabilities
Liabilities
|
3825000 | usd |
| CY2024Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2023Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2024Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
41000 | usd |
| CY2024Q1 | APYP |
Stock Payables
StockPayables
|
657000 | usd |
| CY2023Q4 | APYP |
Stock Payables
StockPayables
|
559000 | usd |
| CY2024Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
3719000 | usd |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-7570000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-3153000 | usd |
| CY2024Q1 | us-gaap |
Minority Interest
MinorityInterest
|
-14000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-3167000 | usd |
| CY2024Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
658000 | usd |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
13000 | usd |
| CY2024Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
3000 | usd |
| CY2024Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
54000 | usd |
| CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
294000 | usd |
| CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
427000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-398000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-436000 | usd |
| CY2024Q1 | APYP |
Change In Fair Value Of Convertible Loans And Warrant Liability
ChangeInFairValueOfConvertibleLoansAndWarrantLiability
|
-824000 | usd |
| CY2023Q1 | APYP |
Change In Fair Value Of Convertible Loans And Warrant Liability
ChangeInFairValueOfConvertibleLoansAndWarrantLiability
|
166000 | usd |
| CY2024Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-22000 | usd |
| CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-19000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-1244000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-289000 | usd |
| CY2024Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-1244000 | usd |
| CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-289000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1244000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-289000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.003 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.003 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.001 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.001 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
380266957 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
380266957 | shares |
| CY2023Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-2553000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
147000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1244000 | usd |
| CY2024Q1 | APYP |
Stock To Be Issued During Period Value Issued For Services
StockToBeIssuedDuringPeriodValueIssuedForServices
|
25000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
383000 | usd |
| CY2024Q1 | APYP |
Stock To Be Issued During Period Value Issued To Investors
StockToBeIssuedDuringPeriodValueIssuedToInvestors
|
75000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-3167000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-2563000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-2563000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
279000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-289000 | usd |
| CY2023Q1 | APYP |
Shares To Be Issued During Period Value
SharesToBeIssuedDuringPeriodValue
|
1000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
161000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-2411000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-2411000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1244000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-289000 | usd |
| CY2024Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
6000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
6000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
172000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
279000 | usd |
| CY2024Q1 | APYP |
Financial Income Net Including Changes In Convertible Loans And Warrants
FinancialIncomeNetIncludingChangesInConvertibleLoansAndWarrants
|
-824000 | usd |
| CY2023Q1 | APYP |
Financial Income Net Including Changes In Convertible Loans And Warrants
FinancialIncomeNetIncludingChangesInConvertibleLoansAndWarrants
|
147000 | usd |
| CY2024Q1 | APYP |
Financial Expenses Net
FinancialExpensesNet
|
14000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-11000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-1000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-24000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
74000 | usd |
| CY2024Q1 | APYP |
Increase Decrease In Accounts Payable To Related Parties
IncreaseDecreaseInAccountsPayableToRelatedParties
|
-16000 | usd |
| CY2023Q1 | APYP |
Increase Decrease In Accounts Payable To Related Parties
IncreaseDecreaseInAccountsPayableToRelatedParties
|
-21000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-257000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-97000 | usd |
| CY2024Q1 | APYP |
Research And Development Expenses Capitalization
ResearchAndDevelopmentExpensesCapitalization
|
50000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-50000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
381000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
141000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
75000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
456000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
141000 | usd |
| CY2024Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
3000 | usd |
| CY2023Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-4000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
152000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
40000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
222000 | usd |
| CY2022Q4 | us-gaap |
Convertible Debt
ConvertibleDebt
|
2257000 | usd |
| CY2023 | us-gaap |
Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium
AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium
|
153000 | usd |
| CY2023 | APYP |
Conversion Of Convertible Loan
ConversionOfConvertibleLoan
|
-243000 | usd |
| CY2023 | APYP |
Decrease Of Notes Purchased
DecreaseOfNotesPurchased
|
-530000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
373000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
100000 | usd |
| CY2024Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p id="xdx_807_eus-gaap--NatureOfOperations_zWtXn8mIsdO2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>- </b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82C_z4YePrlvmBCb">GENERAL</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AppYea, Inc. (“AppYea”, “the Company”, “we” or “us”) was incorporated in the State of South Dakota on November 26, 2012 to engage in the acquisition, purchase, maintenance and creation of mobile software applications. The Company is in the development stage with no significant revenues and no operating history. On November 1, 2021 the Company was redomiciled in the State of Nevada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s common stock is traded on the OTC Markets, OTCQB tier, under the symbol “APYP”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">SleepX LTD is a company formed under the laws of the State of Israel and a wholly owned subsidiary of the Company (“SleepX”). SleepX is a research and development company that has developed a proprietary product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the Company started serial production in 2023. Subject to raising working capital, of which no assurance can be provided, the Company intends to focus on further development and commercialization of its products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">SleepX has incorporated, together with an unrelated third party, a privately held company under the laws of the State of Israel named Ta-nooma Ltd. (“Ta-nooma”). Ta-nooma has developed sleeping monitoring technology for which patent applications were filed and has no revenue from operations. Since its incorporation and as of the financial statements date, Sleepx holds 66.7% of the voting interest of Ta-nooma.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><b>Strategic Development</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The company flagship product is AppySleep – A Biofeedback snoring treatment wristband, combined with the AppySleep App (“AppySleep”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The AppySleep product is currently in serial manufacturing and commercial stage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial position</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements are presented on a going-concern basis. To date, the Company has not generated any significant revenues, suffered recurring losses from operations, incurred negative cash flows from operating activities, and is dependent upon external sources for financing its operations. As of March 31, 2024, the Company had an accumulated deficit of $<span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn3d_di_c20240331_zCkDGBB2c4Q4" title="Accumulated deficit">7,570,000</span> and a stockholders’ deficiency of $<span id="xdx_90A_eus-gaap--StockholdersEquity_iI_pn3d_di_c20240331_zTY4ICErBMh3" title="Stockholders' deficiency">3,153,000</span>. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The Company intends to continue to finance its operating activities by raising capital. There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research and development activities on commercially reasonable terms or at all. If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development of its product candidates or may be required to implement cost reduction measures and may be required to delay part of its development programs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments for the values of assets and liabilities and their classification that may be necessary in the event that the Company is no longer able to continue its operations as a “going concern”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>APPYEA INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO THE FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> | |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-7570000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-3153000 | usd |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p id="xdx_84B_eus-gaap--UseOfEstimates_zb3DXC6H6DK5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zn6R9xkCj7Yl">Use of Estimates in Preparation of Financial Statements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP accounting principles requires management to make estimates and assumptions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | |
| CY2024Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
267000 | usd |
| CY2023Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
498000 | usd |
| CY2024Q1 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
208000 | usd |
| CY2023Q4 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
129000 | usd |
| CY2024Q1 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
79000 | usd |
| CY2023Q4 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
79000 | usd |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
116000 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
721000 | usd |
| CY2024Q1 | us-gaap |
Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
|
190000 | usd |
| CY2023Q1 | us-gaap |
Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
|
1067000 | usd |
| CY2023Q4 | us-gaap |
Convertible Debt
ConvertibleDebt
|
1203000 | usd |
| CY2024Q1 | APYP |
Change In Fair Value Of Convertible Loans Liability Through Profit Or Loss
ChangeInFairValueOfConvertibleLoansLiabilityThroughProfitOrLoss
|
-957000 | usd |
| CY2023 | APYP |
Change In Fair Value Of Convertible Loans Liability Through Profit Or Loss
ChangeInFairValueOfConvertibleLoansLiabilityThroughProfitOrLoss
|
434000 | usd |
| CY2024Q1 | us-gaap |
Convertible Debt
ConvertibleDebt
|
2160000 | usd |
| CY2023Q4 | us-gaap |
Convertible Debt
ConvertibleDebt
|
1203000 | usd |
| CY2023Q4 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
152750 | usd |
| CY2023 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
242538 | usd |
| CY2023 | us-gaap |
Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
|
8634616 | shares |
| CY2024Q1 | us-gaap |
Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
|
P0Y2M15D | |
| CY2023Q4 | us-gaap |
Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
|
P0Y5M15D | |
| CY2023Q4 | APYP |
Convertible Amortized Cost
ConvertibleAmortizedCost
|
796000 | usd |
| CY2023 | APYP |
Transition From Convertible Loans Measured At Fair Value To Measurement At Amortized Cost
TransitionFromConvertibleLoansMeasuredAtFairValueToMeasurementAtAmortizedCost
|
530000 | usd |
| CY2023 | us-gaap |
Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
|
66000 | usd |
| CY2023 | APYP |
Financial Expenses Related To Transition From Fair Value Measurement To Amortized Cost
FinancialExpensesRelatedToTransitionFromFairValueMeasurementToAmortizedCost
|
304000 | usd |
| CY2024Q1 | APYP |
Accrued Interest In Profit And Loss
AccruedInterestInProfitAndLoss
|
15000 | usd |
| CY2023 | APYP |
Accrued Interest In Profit And Loss
AccruedInterestInProfitAndLoss
|
28000 | usd |
| CY2024Q1 | APYP |
Convertible Amortized Cost
ConvertibleAmortizedCost
|
811000 | usd |
| CY2023Q4 | APYP |
Convertible Amortized Cost
ConvertibleAmortizedCost
|
796000 | usd |
| CY2024Q1 | us-gaap |
Investment Company Amount Received To Nav Excess Less
InvestmentCompanyAmountReceivedToNavExcessLess
|
456431 | usd |
| CY2024Q1 | us-gaap |
Investment Owned Balance Shares
InvestmentOwnedBalanceShares
|
7500000 | shares |
| CY2024Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
49492 | usd |
| CY2024Q1 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
197966 | usd |
| CY2024Q1 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false |
